Genetic Discovery Yields Prostate Cancer Test, Promise of Future Therapy
A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment. The analysis, published in the American Journal of Pathology, found that prostate cancer patients who carry certain genetic mutations have a 91 percent chance of their cancer recurring. McGowan Institute for Regenerative Medicine affiliated faculty member George Michalopoulos, M.D., Ph.D., professor and chairman of the Department of Pathology at the University of Pittsburgh, was a member of the study’s research team. This research was funded by the National Institutes of Health (NIH), American Cancer Society, and University of Pittsburgh Cancer Institute (UPCI).